Dexcel Pharma USA, a subsidiary of Israeli pharmaceutical company Dexcel Pharma, announced on Tuesday that it has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, the generic equivalent of OFEV (nintedanib) capsules.
Nintedanib is indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a serious and progressive lung disease.
Dexcel said that the product will be available through specialty pharmacy and established pharmaceutical distribution channels, helping to ensure reliable access for patients across the United States.
OFEV is a brand of Boehringer Ingelheim International GmbH.
Viatris' RYZUMVI receives US FDA Approval to treat presbyopia
Omeros receives negative EU opinion on narsoplimab after re-examination
Ionis' TRYNGOLZA recommended for EU approval in severe hypertriglyceridemia
FDA approves Genentech's Enspryng as first at-home subcutaneous treatment for thyroid eye disease
EMA issues positive CHMP opinion for Revolution Medicines' RASONQUE in metastatic pancreatic cancer
Edesa Biotech receives FDA clearance to expand EB06 vitiligo study into the US
LTR Pharma launches Roxus nasal spray for ED in the US
Genezen agrees manufacturing collaboration with Galibra Neuroscience
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
FDA approves Vantis Vascular's 6F CrossFAST model
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
ArkBio reports FDA clearance of IND application for AK0406
Agilent to acquire Proscia for up to USD270m to expand digital pathology capabilities